Abarceo Pharma
  • About
  • Team
    • Management
    • Board
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page
Abarceo attended the Almi Invest Rooftop Mingle on May 7

Abarceo attended the Almi Invest Rooftop Mingle on May 7

by SD-AbarceoPharma | May 15, 2026 | Events, Investors

Abarceo’s CEO Adam Bruce participated at the Almi Invest Rooftop Mingle on May 7th and gave an inspiring presentation. “I’m grateful for the opportunity to take part in this important event,” says Adam Bruce.          ...
Redeye Theme Event Diabetes 2026

Redeye Theme Event Diabetes 2026

by SD-AbarceoPharma | Apr 30, 2026 | Diabetes, Events, Investors, News & Press releases

Abarceo is participating in the upcoming Redeye Theme Event Diabetes 2026! We’re proud to present Abarceo at the main diabetes business and finance event in Sweden, The Redeye Theme Event Diabetes 2026 on May 6! This focused seminar is intended to give investors...

Investing in Life Science 2024 – Presentation

by SD-AbarceoPharma | Nov 14, 2024 | Events, Investors, News & Press releases

Adam Bruce, CEO & Chair of Abarceo Pharma, presents at Investing in Life Science – From Seed To Success. About the event On September 12, 2024, BioStock and Vator Securities hosted the investment-focused event, Investing in Life Science: From Seed to...

Investing in Life Science 2024 – Interview

by SD-AbarceoPharma | Nov 14, 2024 | Events, Investors, News & Press releases

BioStock’s Natasha Bank interviews Adam Bruce, CEO & Chair of Abarceo Pharma, at Investing in Life Science – From Seed To Success.    About the event On September 12, 2024, BioStock and Vator Securities hosted the investment-focused event, Investing in Life...
Rapidus: Diabetes companies collect SEK 21.5 million (article in Swedish)

Rapidus: Diabetes companies collect SEK 21.5 million (article in Swedish)

by SD-AbarceoPharma | Mar 1, 2021 | Diabetes, Investors, News & Press releases

Abarceo Pharma får Almi Invest som ny delägare när de nu tar in total 21,5 miljoner kroner. Pengarna ska räcka i ett år och bland annat användas för att bestämma vilken läkemedelskandidat som de ska utveckla vidare. Bolaget har i nuläget flera möjliga kandidater för...

Recent Posts

  • Abarceo attended the Almi Invest Rooftop Mingle on May 7
  • Redeye Theme Event Diabetes 2026
  • RESI Europe 2026
  • Abarceo attended ATTD
  • World Diabetes Day

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2026 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy